Balyasny Asset Management
VKTX icon

Balyasny Asset Management’s Viking Therapeutics VKTX Stock Holding History

Balyasny Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.52M Buy
115,906
+79,413
+218% +$2.57M 0.01% 1415
2026
Q1 		$1.19M Buy
+36,493
New +$1.17M ﹤0.01% 2011
2025
Q2 		– Sell
-1,648,628
Closed -$43.4M – 3395
2025
Q1 		$39.8M Buy
1,648,628
+788,179
+92% +$24.9M 0.07% 365
2024
Q4 		$34.6M Buy
+860,449
New +$49.1M 0.05% 444
2024
Q3 		– Sell
-185,382
Closed -$10.9M – 3194
2024
Q2 		$9.83M Buy
185,382
+76,787
+71% +$5.03M 0.02% 900
2024
Q1 		$8.9M Sell
108,595
-2,134,928
-95% -$95M 0.02% 984
2023
Q4 		$41.8M Buy
2,243,523
+121,624
+6% +$1.59M 0.08% 316
2023
Q3 		$23.5M Buy
2,121,899
+1,506,631
+245% +$21.5M 0.05% 520
2023
Q2 		$9.97M Buy
615,268
+58,661
+11% +$1.23M 0.02% 782
2023
Q1 		$9.27M Buy
556,607
+452,837
+436% +$4.68M 0.02% 811
2022
Q4 		$975K Sell
103,770
-2,569,794
-96% -$11.5M ﹤0.01% 1676
2022
Q3 		$7.27M Buy
2,673,564
+30,613
+1% +$100K 0.02% 831
2022
Q2 		$7.64M Buy
+2,642,951
New +$6.54M 0.02% 749
2020
Q3 		– Sell
-10,410
Closed -$75K – 1628
2020
Q2 		$75K Buy
+10,410
New +$69.1K ﹤0.01% 1066
2019
Q4 		– Sell
-10,245
Closed -$70K – 1513
2019
Q3 		$70K Sell
10,245
-8,233
-45% -$61.1K ﹤0.01% 1104
2019
Q2 		$153K Sell
18,478
-43,180
-70% -$369K ﹤0.01% 1411
2019
Q1 		$613K Sell
61,658
-301,948
-83% -$2.53M ﹤0.01% 1152
2018
Q4 		$2.78M Sell
363,606
-731,245
-67% -$8.74M 0.02% 633
2018
Q3 		$19.1M Buy
1,094,851
+839,851
+329% +$9.99M 0.09% 313
2018
Q2 		$2.42M Buy
+255,000
New +$1.7M 0.01% 870

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Balyasny Asset Management's VKTX Position: Q2 2026 in Review

Balyasny Asset Management increased its Viking Therapeutics (VKTX) stake by 218% in Q2 2026, buying an estimated $2.57M and bringing the position to 115,906 shares worth $4.52M. The position accounts for 0.01% of the portfolio, ranked #1415.

Balyasny Asset Management first reported a position in VKTX in Q2 2018 and has held it in 20 quarters since. The position peaked at $41.8M in Q4 2023. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Balyasny Asset Management held 115,906 shares of Viking Therapeutics worth $4.52M as of Q2 2026.
  • Balyasny Asset Management bought 79,413 Viking Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Viking Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1415 holding.
  • Balyasny Asset Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • Balyasny Asset Management's Viking Therapeutics position peaked at $41.8M in Q4 2023.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.